Purpose
The aim of this study was to evaluate the applicability of125 I-labeled carcinoembryonic antigen-specific monoclonal antibody CL58 in clinical radioimmunoguided surgery for colorectal cancer. METHODS: First, we tested the purity and affinity constant of CL58 and measured the binding affinity of CL58 to colorectal cancer cells and normal cells. Second, we injected125I-labeled CL58 into nude mice with colon cancers. Then, samples from the tumor, blood, and normal tissues of injected mice were weighed and counted in a gamma-ray counter for assessment of biodistribution. Finally, we administered125Habeled CL58 submucosally in 29 patients with colorectal cancer via endoscope. Radioimmunoguided surgery was performed 3 to 14 days later with a portable gamma-detecting probe to obtain the counts in the target sites. Tumor-to-normal tissue ratio of 3 was taken as the lowest positive threshold value for primary lesions, wall infiltration, and lymph node metastasis. In addition, all the samples were examined by routine histopathology. Lymph nodes negative by routine histopathology were subjected to immunohistochemical staining with anticytokeratin to detect the lymphatic micrometastasis. RESULTS: The affinity constant of CL58 was 7.5 X 1010 M-. Moreover, CL58 reacted strongly to the colorectal cancer cell lines, but not to the normal control cells. Furthermore, the tumor tissues showed significant intake of125I-labeled CL58, as compared with that of normal tissues. The sensitivity of radioimmunoguided surgery in detecting primary lesions was 93-1 percent, and the specificity of radioimmunoguided surgery to correctly identify negative incisional margins for tumor infiltration was 95.5 percent. For the detection of lymphatic metastasis, the sensitivity of radioimmunoguided surgery was 92.0 percent and the specificity was 87.8 percent. The sensitivity of radioimmunoguided surgery in detecting lymph node metastasis was significantly higher when compared with traditional clinical methods (P = 0.0087). The specificity of radioimmunogu-Supported by a research grant from the National “863” project of China (No. 2001AA215371).
Similar content being viewed by others
References
Zhen S. Recent study on colorectal cancer in China: early detection and novel related gene. Chin Med J 1998;110:309–10.
Muxi A, Pons F, Vidal-Sicart S,et al. Radioimmunoguided surgery of colorectal carcinoma with an 1111n-labelled anti-TAG72 monoclonal antibody. Nucl Med Commun 1999;20:123–30.
Kotanagi H, Fukuoka T, Shibata Y,et al. The size of regional lymph nodes dose not correlate with the presence or absence of metastasis in lymph nodes in rectal cancer. J Surg Oncol 1993;54:252–4.
Mayer A, Tsiompanou E, Denise O,et al. Radioimmu-noguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711–9.
Haddad R, Avital S, Troitsa A,et al. Benefits of radio-immunoguided surgery for pelvic recurrence. EurJ Surg Oncol 2001;27:298–301.
Bakalakos EA, Young DC, Martin EW Jr,et al. Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann Surg Oncol 1998; 5:590–4.
Stramignoni D, Bowen R, Atkinson B F,et al. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 1983;31:542–52.
Kim JC, Kim WS, Ryu JS,et al. Applicability of carcinoembryonic antigen-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma. Cancer Res 2000;60:4825–9.
Lin BH, Yang Z, Zhang MY,et al. Preliminary study of RIS in 26 cancer patients. Chinese J Nucl Med 1997; 17:116.
Xu G, Zhang M, Liu B,et al. Radioimmunoguided surgery in gastric cancer using 1311 labeled monoclonal antibody 3H11. Semin Surg Oncol 1994;10:88–94.
Yang Z, Li Z, Zhang M,et al. Study of 99mTc/188Re labeled anti-CEA MAb CL58 and its biodistribution. Chin J Nucl Med 2000;20:228–9.
Obuchowski NA. On the comparison of correlated proportions for clustered data. Stat Med 1998;17:1495–507.
Percivale P, Bertoglio S, Meszaros P,et al. Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer. Semin Surg Oncol 1998;15:231–4.
Nieroda CA, Mojzisik C, Sardi A,et al. The impact of radioimmunoguided surgery (RIGSTM) on surgical decision-making in colorectal cancer. Dis Colon Rectum 1989, 32:927–32.
Zhao HY. Nuclear medicine. Shanghai publishing company of scientific technology 1979:127.
Deguchi T, Doi T, Ehara H,et al. Detection of micro-metastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53:5350–4.
Hayashi N, Arakawa H, Nagase H,et al. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res 1994; 54:3853–6.
Author information
Authors and Affiliations
About this article
Cite this article
Gu, J., Zhao, J., Li, Z. et al. Clinical application of radioimmunoguided surgery in colorectal cancer using125i-labeled carcinoembryonic antigen-specific monoclonal antibody submucosally. Dis Colon Rectum 46, 1659–1666 (2003). https://doi.org/10.1007/BF02660772
Issue Date:
DOI: https://doi.org/10.1007/BF02660772